The European Patent Office declared a contested mRNA patent owned by Moderna (MRNA) invalid, handing a win to BioNTech (BNTX) and its partner Pfizer (PFE), Ludwig Burger and Patricia Weiss report, citing a statement from the European Patent Office. Moderna told Reuters that it disagreed with the office’s decision and would lodge an appeal. Shares of Moderna are down 2% to $77.08 in morning trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRNA: